Skip to content

Karyopharm Therapeutics Inc.

KPTI

CIK 0001503802

← back to feed
Revenue (TTM)
$147.05M
+0.6% YoY Q1 May 2026
Net Income (TTM)
−$116.23M
−156.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$12.15
−28.1% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-67.7%
Q1 May 2026
Net Margin
-79.0%
Q1 May 2026
Free Cash Flow (TTM)
−$124.62M
Q1 May 2026
Cash
$90.85M
Q1 May 2026
Total Debt
$169.29M
Q1 May 2026
Shares Outstanding
22.66M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings